Corbus Pharmaceuticals Holdings, Inc. – NASDAQ:CRBP

Add to watchlist

$9.13

-3.61

-28.39%

Market closed

Open in about 5 hours

-78.35%

month

-78.35%

quarter

+120.40%

year

Market Cap	155.04M
Enterprise value	42.29M

P/E	-0.67
EV/Sales	N/A
EV/EBITDA	-0.98
Price/Sales	N/A
Price/Book	1.03
PEG ratio	-0.07
EPS	-6.96

Revenue	N/A
EBITDA	-36.72M
Income	-33.75M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Corbus Pharmaceuticals Holdings Stock Forecast

M Q Y

Last Year

$59.4

Potential upside: 550.60%

Analysts Price target
Financials & Ratios estimates

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP): Profit margin
Jun 2023	0	-8.78M
Sep 2023	0	-10.05M
Dec 2023	1.34M	-8.02M	-594.27%
Mar 2024	0	-6.89M

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP): Debt to assets
Jun 2023	43723383	34.20M	78.23%
Sep 2023	36283405	35.97M	99.14%
Dec 2023	28272393	35.17M	124.42%
Mar 2024	125744162	28.77M	22.89%

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP): Cash Flow
Jun 2023	-7.80M	8.80M	17.68K
Sep 2023	-7.17M	10.89M	-820.50K
Dec 2023	-6.00M	10.38M	-1.90M
Mar 2024	-7.96M	-98.23M	106.58M

Corbus Pharmaceuticals Holdings alternative data

Corbus Pharmaceuticals Holdings
Employees

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP): Employee count
Aug 2023	33
Sep 2023	33
Oct 2023	33
Nov 2023	33
Dec 2023	33
Jan 2024	33
Feb 2024	33
Mar 2024	19
Apr 2024	19
May 2024	19
Jun 2024	19
Jul 2024	19

Corbus Pharmaceuticals Holdings
Hedge Funds Holdings Q2 2022

43.05% -7.62%

of CRBP is owned by hedge funds

58 -4

hedge funds hold CRBP stock

31.80M -5.63M

shares is hold by hedge funds

CRBP hedge funds holdings changes

Corbus Pharmaceuticals Holdings
Insider Trading

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP): Insider trades (number of shares)
Period	Buy	Sel
Jan 2024	282632	0
Feb 2024	750000	0
Mar 2024	550000	0

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Option	14 Jun 2024	HOLMER ALAN F director director	Common Stock, par value $0.0001 per share	1,667	$30	$50,010
Option	14 Jun 2024	HOLMER ALAN F director director	Options to purchase common stock	1,667	$30	$50,010
Option	10 Apr 2024	MORAN SEAN F. officer: Chief Financial Officer officer: Chief Financial Officer	Common Stock	1,787	$30	$53,610
Option	10 Apr 2024	MORAN SEAN F. officer: Chief Financial Officer officer: Chief Financial Officer	Employee Stock Option (right to buy)	1,787	$30	$53,610
Purchase	8 Mar 2024	CORMORANT ASSET MANAGEMENT, LP 10 percent owner 10 percent owner	Common Stock	8,862	$45.96	$407,298
Purchase	8 Mar 2024	CORMORANT ASSET MANAGEMENT, LP 10 percent owner 10 percent owner	Common Stock	156,597	$45.26	$7,087,580
Purchase	8 Mar 2024	CORMORANT ASSET MANAGEMENT, LP 10 percent owner 10 percent owner	Common Stock	61,668	$44.62	$2,751,626
Purchase	8 Mar 2024	CORMORANT ASSET MANAGEMENT, LP 10 percent owner 10 percent owner	Common Stock	18,548	$43.26	$802,386
Purchase	8 Mar 2024	CORMORANT ASSET MANAGEMENT, LP 10 percent owner 10 percent owner	Common Stock	24,983	$42.25	$1,055,532
Purchase	8 Mar 2024	CORMORANT ASSET MANAGEMENT, LP 10 percent owner 10 percent owner	Common Stock	29,342	$41.23	$1,209,771

CRBP insider trading transactions

Corbus Pharmaceuticals Holdings
Earnings Call Transcripts

Quarter	Transcript
Q4 2020 15 Mar 2021	Q4 2020 Earnings Call Transcript
Q2 2020 6 Aug 2020	Q2 2020 Earnings Call Transcript
Q1 2020 11 May 2020	Q1 2020 Earnings Call Transcript
Q4 2019 12 Mar 2020	Q4 2019 Earnings Call Transcript

CRBP earnings call transcripts

Corbus Pharmaceuticals Holdings
Executives

Insider	Age	Since	Compensation
Dr. Yuval Cohen (1975) Chief Executive Officer & Director	50		$827,320
Mr. Sean F. Moran CPA, M.B.A., CPA, MBA (1958) Chief Financial Officer	67		$528,000

Corbus Pharmaceuticals Holdings
Latest News

Monday, 9 December 2024
07:00	Corbus Pharmaceuticals Announces Dosing of First Patient in its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors	globenewswire.com
Tuesday, 3 December 2024
07:00	FDA Grants Fast Track Designation to CRB-701 for the Treatment of Relapsed or Refractory Metastatic Cervical Cancer	globenewswire.com
Monday, 11 November 2024
04:12	Corbus Pharmaceuticals' Sell-Off: Speculative Entry Price In Oncology And Obesity Therapies	seekingalpha.com
Tuesday, 29 October 2024
08:00	Corbus Pharmaceuticals to Present at the Guggenheim Securities Healthcare Innovation Conference	globenewswire.com
Wednesday, 16 October 2024
08:00	Corbus Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701)	globenewswire.com
Sunday, 29 September 2024
09:15	Check Out Last Week's Big Insider Buying: Biotechs, Energy, and More	247wallst.com
Thursday, 26 September 2024
08:00	Corbus Pharmaceuticals to Participate in the BMO Capital Markets' Oncology Summit	globenewswire.com
Monday, 23 September 2024
14:01	Nasdaq-Traded Cannabinoid Biotech Corbus Pharma Stock Plunges 60%, But Analysts Say 'Buy The Dip' Now	benzinga.com
Sunday, 8 September 2024
07:43	3 Crazy Stocks to Buy That Are Outperforming Nvidia in 2024	247wallst.com
Monday, 26 August 2024
12:00	Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts say	marketwatch.com
10:55	Wall Street Analysts Think Corbus Pharmaceuticals (CRBP) Could Surge 43.82%: Read This Before Placing a Bet	zacks.com
Tuesday, 20 August 2024
08:00	Corbus Pharmaceuticals Strengthens Board of Directors with Appointment of Winston Kung	globenewswire.com
Friday, 9 August 2024
13:01	Corbus Pharmaceuticals (CRBP) Upgraded to Buy: Here's Why	zacks.com
10:55	Wall Street Analysts Believe Corbus Pharmaceuticals (CRBP) Could Rally 54.24%: Here's is How to Trade	zacks.com
Tuesday, 6 August 2024
08:00	Corbus Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Corporate Update	globenewswire.com
Tuesday, 30 July 2024
08:50	Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences in August	globenewswire.com
Sunday, 30 June 2024
10:13	Treasure Hunt: 3 Small-Cap Stocks Wall Street Hasn't Discovered Yet	investorplace.com
Monday, 3 June 2024
13:03	Corbus: Nectin-4 Targeting Proven With U.S. Data On The Way Early 2025	seekingalpha.com
Saturday, 1 June 2024
10:00	SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumors in a Clinical Update Presented at ASCO 2024	globenewswire.com
Thursday, 30 May 2024
08:00	Corbus Pharmaceuticals to Present at the 45th Annual Goldman Sachs Global Healthcare Conference	globenewswire.com
Thursday, 23 May 2024
17:05	Updated Phase 1 Clinical Data for SYS-6002 (CRB-701) to be presented at 2024 ASCO Annual Meeting	globenewswire.com
Thursday, 9 May 2024
08:00	Corbus Pharmaceuticals to Participate in the 2024 RBC Capital Markets Global Healthcare Conference	globenewswire.com
Tuesday, 7 May 2024
08:00	Corbus Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update	globenewswire.com
Wednesday, 1 May 2024
08:00	Corbus Pharmaceuticals to Participate in the BTIG Obesity Health Forum	globenewswire.com
Wednesday, 24 April 2024
16:05	Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO Annual Meeting	globenewswire.com
Friday, 19 April 2024
14:30	These 3 Small-Cap Stocks Are Up 304% in 2024. Can They Run Higher?	InvestorPlace
Sunday, 17 March 2024
09:10	Buffett Can't Get Enough of This Stock, Plus Other Insider Buying	24/7 Wall Street
Friday, 15 March 2024
09:51	What Makes Corbus Pharmaceuticals (CRBP) a Good Fit for 'Trend Investing'	Zacks Investment Research
Friday, 8 March 2024
20:02	All Three of Our Analysts Agree	InvestorPlace
Tuesday, 6 February 2024
09:50	Corbus Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	GlobeNewsWire

Ideas & Opinions

Seeking Alpha 17 Jun 2025

Corbus Pharmaceuticals: Is Its Pipeline Really Worthless After Novo's Negative Data?
Seeking Alpha 9 Jul 2024

Biotech Stocks 2024 Second Half Outlook - Buy Biotechs
Seeking Alpha 3 Jun 2024

Corbus: Nectin-4 Targeting Proven With U.S. Data On The Way Early 2025
Seeking Alpha 30 Jan 2024

Corbus: Ability To Have Best-In-Class Nectin-4 Targeting Drug
Seeking Alpha 29 Jan 2024

Corbus Pharmaceuticals: Surging On The Back Of Great News, But I See Dark Clouds
Seeking Alpha 20 Feb 2023

Week In Review: China Biopharmas Announce 3 Out-Licensing Deals Totaling $2 Billion
Seeking Alpha 15 Apr 2021

Corbus: Assessing If Lenabasum Can Finally Break Through

Frequently Asked Questions (FAQ)

What's the price of Corbus Pharmaceuticals Holdings stock today?

One share of Corbus Pharmaceuticals Holdings stock can currently be purchased for approximately $9.13.
When is Corbus Pharmaceuticals Holdings's next earnings date?

Unfortunately, Corbus Pharmaceuticals Holdings's (CRBP) next earnings date is currently unknown.
Does Corbus Pharmaceuticals Holdings pay dividends?

No, Corbus Pharmaceuticals Holdings does not pay dividends.
How much money does Corbus Pharmaceuticals Holdings make?

Corbus Pharmaceuticals Holdings has a market capitalization of 155.04M.
What is Corbus Pharmaceuticals Holdings's stock symbol?

Corbus Pharmaceuticals Holdings, Inc. is traded on the NASDAQ under the ticker symbol "CRBP".
What is Corbus Pharmaceuticals Holdings's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Corbus Pharmaceuticals Holdings?

Shares of Corbus Pharmaceuticals Holdings can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Corbus Pharmaceuticals Holdings's key executives?
Corbus Pharmaceuticals Holdings's management team includes the following people:
- Dr. Yuval Cohen Chief Executive Officer & Director(age: 50, pay: $827,320)
- Mr. Sean F. Moran CPA, M.B.A., CPA, MBA Chief Financial Officer(age: 67, pay: $528,000)
How many employees does Corbus Pharmaceuticals Holdings have?

As Jul 2024, Corbus Pharmaceuticals Holdings employs 19 workers.
When Corbus Pharmaceuticals Holdings went public?

Corbus Pharmaceuticals Holdings, Inc. is publicly traded company for more then 10 years since IPO on 27 Oct 2014.
What is Corbus Pharmaceuticals Holdings's official website?

The official website for Corbus Pharmaceuticals Holdings is corbuspharma.com.
Where are Corbus Pharmaceuticals Holdings's headquarters?

Corbus Pharmaceuticals Holdings is headquartered at 500 River Ridge Drive, Norwood, MA.
How can i contact Corbus Pharmaceuticals Holdings?

Corbus Pharmaceuticals Holdings's mailing address is 500 River Ridge Drive, Norwood, MA and company can be reached via phone at +61 79630100.
What is Corbus Pharmaceuticals Holdings stock forecast & price target?

Based on 4 Wall Street analysts` predicted price targets for Corbus Pharmaceuticals Holdings in the last 12 months, the avarage price target is $59.4. The average price target represents a 550.60% change from the last price of $9.13.

Corbus Pharmaceuticals Holdings, Inc.

corbuspharma.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

+61 79630100

500 River Ridge Drive
Norwood, MA 02062

CIK: 0001595097
ISIN: US21833P3010
CUSIP: 21833P103